Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Buy rating on PROCEPT BioRobotics (NASDAQ:PRCT) and raises the price target from $55 to $58.
February 28, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on PROCEPT BioRobotics and raises the price target from $55 to $58.
The upgrade in price target by Truist Securities from $55 to $58 reflects a positive outlook on PROCEPT BioRobotics, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100